<DOC>
	<DOC>NCT02011386</DOC>
	<brief_summary>The study investigates different criteria for remission based on MRI and circulating biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates factors that affect disease activity, function and participation by use of different questionnaires.</brief_summary>
	<brief_title>Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Axial spondyloarthritis according to the ASAS classification criteria Sacroiliitis on conventional Xrays or MRI. Disease activity assessed by BASDAI &gt;40 mm despite treatment with NSAID. Clinical indication for tumornecrosisfactoralpha inhibitor treatment by the treating physician. No contraindications for tumornecrosisfactoralpha inhibitor No contraindications for MRI No contraindications in participation in a study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>